What is Vertex Pharmaceuticals's subpart f income, net of credits?

Vertex Pharmaceuticals (VRTX) reported subpart f income, net of credits of -$24.35M in Q4 2025.

What does subpart f income, net of credits mean?

The tax impact of income earned by foreign subsidiaries that is subject to current U.S. taxation.

Subpart F income, net of credits

Vertex Pharmaceuticals Subpart F income, net of credits remained flat by 0.0% to -$24.35M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementIncome Statement

SectionOther

CategoryRisk

SignalLower is better

VolatilityModerate

First reportedQ1 2025

Last reportedQ4 2025Feb 13, 2026

How to read this metric

High levels of Subpart F income may indicate higher tax costs on foreign earnings.

Detailed definition

This captures the tax impact of Subpart F income, which relates to certain types of passive or easily movable income ear...

Peer comparison

Standard disclosure for multinational companies with foreign subsidiaries.

Metric ID: other_effective_income_tax_rate_reconciliation_cross_bor_4a49be

Historical Data

1 years

	FY'25
Value	-$97.40M

Subpart F income, net of credits at Other Companies

GE VernovaGEV View metric

CDN

CDNCDN View metric

GE VernovaGEV View metric

CDN

CDNCDN View metric

Willis Towers WatsonWTW View metric

GE VernovaGEV View metric

Frequently Asked Questions

What is Vertex Pharmaceuticals's subpart f income, net of credits?: Vertex Pharmaceuticals (VRTX) reported subpart f income, net of credits of -$24.35M in Q4 2025.
What does subpart f income, net of credits mean?: The tax impact of income earned by foreign subsidiaries that is subject to current U.S. taxation.